{"DataElement":{"publicId":"3397490","version":"1","preferredName":"Medication Nonsteroidal Antiinflammatory Drug Use Type","preferredDefinition":"Types of anti-inflammatory agents (non-steroids) taken.","longName":"3397455v1.0:3397489v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"3397455","version":"1","preferredName":"Medication Nonsteroidal Antiinflammatory Drug Use","preferredDefinition":"A manner, or usual, or accepted practice of using anti-inflammatory agents that are not steroids.","longName":"2411879v1.0:3397453v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2411879","version":"1","preferredName":"Medication","preferredDefinition":"biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.","longName":"C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"019C7266-B896-0AAA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"ONEDATA","dateModified":"2005-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3397453","version":"1","preferredName":"Nonsteroidal Antiinflammatory Drug Use","preferredDefinition":"Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain NSAIDs also may inhibit lipoxygenase enzymes or phospholipase C or may modulate T-cell function. (AMA Drug Evaluations Annual, 1994, p 1814-5):A manner, or usual, or accepted practice of using something.","longName":"C257:C25340","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonsteroidal Antiinflammatory Drug","conceptCode":"C257","definition":"A pharmacological agent that is not a steroid and has potential anti-inflammatory, analgesic, antipyretic and anti-platelet activities. Most nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the conversion of arachidonic acid to the precursors of prostaglandin and thromboxane by cyclooxygenase enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Use","conceptCode":"C25340","definition":"A manner, or usual, or accepted practice of using something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA370D1D-F640-4BCA-E040-BB89AD430F6C","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"ONEDATA","dateModified":"2012-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA370D1D-F651-4BCA-E040-BB89AD430F6C","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3397489","version":"1","preferredName":"Nonsteroidal Antiinflammatory Drug Use Type","preferredDefinition":"Types of anti-inflammatory agents that are not steroids.","longName":"3397489v1.0","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA370D1D-F699-4BCA-E040-BB89AD430F6C","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"ONEDATA","dateModified":"2012-03-01","deletedIndicator":"No"},{"value":"COX-2 inhibitor","valueDescription":"COX-2 inhibitor","ValueMeaning":{"publicId":"3102996","version":"1","preferredName":"COX-2 inhibitor","longName":"3102996","preferredDefinition":"COX-2 inhibitor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87793316-A57A-E52B-E040-BB89AD431F7E","latestVersionIndicator":"Yes","beginDate":"2010-05-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA370D1D-F6A3-4BCA-E040-BB89AD430F6C","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"ONEDATA","dateModified":"2012-03-01","deletedIndicator":"No"},{"value":"Naproxen","valueDescription":"Naproxen","ValueMeaning":{"publicId":"2578314","version":"1","preferredName":"Naproxen","longName":"2578314","preferredDefinition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naproxen","conceptCode":"C680","definition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA370D1D-F6AD-4BCA-E040-BB89AD430F6C","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"ONEDATA","dateModified":"2012-03-01","deletedIndicator":"No"},{"value":"Ibuprofen","valueDescription":"Ibuprofen","ValueMeaning":{"publicId":"2578121","version":"1","preferredName":"Ibuprofen","longName":"2578121v1.00","preferredDefinition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibuprofen","conceptCode":"C561","definition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE36-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"MMADDINENI","dateModified":"2023-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA370D1D-F6B7-4BCA-E040-BB89AD430F6C","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"ONEDATA","dateModified":"2012-03-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3397488","version":"1","preferredName":"Nonsteroidal Antiinflammatory Drug Use Type","preferredDefinition":"Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain NSAIDs also may inhibit lipoxygenase enzymes or phospholipase C or may modulate T-cell function. (AMA Drug Evaluations Annual, 1994, p 1814-5):A manner, or usual, or accepted practice of using something.:Something distinguishable as an identifiable class based on common qualities.","longName":"C257:C25340:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonsteroidal Antiinflammatory Drug","conceptCode":"C257","definition":"A pharmacological agent that is not a steroid and has potential anti-inflammatory, analgesic, antipyretic and anti-platelet activities. Most nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the conversion of arachidonic acid to the precursors of prostaglandin and thromboxane by cyclooxygenase enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Use","conceptCode":"C25340","definition":"A manner, or usual, or accepted practice of using something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA370D1D-F674-4BCA-E040-BB89AD430F6C","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"ONEDATA","dateModified":"2012-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA370D1D-F685-4BCA-E040-BB89AD430F6C","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"CHILLIJ","dateModified":"2013-05-16","changeDescription":"5/16/13 jc moved to SWOG context.  Update VD Representation","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811961","version":"1","longName":"Protocol/Admin.","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Select type of supplement tak","type":"Preferred Question Text","description":"Select type of supplement taken","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA370D1D-F6C1-4BCA-E040-BB89AD430F6C","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeDescription":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}